Vibe Bio blog

Learn how top biopharma BD teams find diamonds in the rough by prioritizing strategic clarity, disciplined pipeline triage, and AI-powered asset tracking.

With capital markets in flux, regulatory headwinds, and scientific risks, boards and executives must navigate pharma strategy and portfolio prioritization.

Jay Andersen, a pioneer in pharmaceutical decision-making, shared lessons learned from developing portfolio management and probability assessment approaches.

Pharma’s business development and licensing (BD&L) teams are at the forefront of identifying new science to support their company’s future.

In biopharma business development, companies face increasing pressure to identify the next blockbuster drug with limited resources and time constraints.

I recently sat down with a Top 20 pharmaceutical company to discuss their goals and struggles for the year ahead and how pharma portfolio analytics fits in.

Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks. 

Chinese biopharma companies are at an inflection point, with rapid advances in science, know-how, and talent; these assets will reshape drug development.

Based on JPM 2025, it’s safe to say that the biotech industry is experiencing a broad resurgence, with subtle yet significant disruption beneath the surface.

By combining human expertise with AI-powered analysis, we’re helping biopharma companies make faster, more informed business development decisions.

Artificial intelligence-powered pipeline analysis is emerging as a tool that can help teams make better, faster drug development decisions.

Implementing guardrails for artificial intelligence (AI) in biopharma is crucial for ensuring effective, safe, and compliant use of this powerful technology.